CT 0596
Alternative Names: CT-0596Latest Information Update: 24 Mar 2026
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Leukaemia; Multiple myeloma
Most Recent Events
- 06 Mar 2026 National Medical Products Administration (NMPA) accepts the IND application for relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL)
- 28 Dec 2025 CARsgen Therapeutics submits Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for Leukaemia
- 28 Dec 2025 CARsgen Therapeutics submits Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for Multiple myeloma